Valuation: Beacon Pharmaceuticals PLC

Market Cap 25.48B 206M 179M 166M 153M 289M 19.6B 292M 1.96B 768M 9.81B 774M 757M 32.48B P/E 2024
68.2x
P/E 2025 25.8x
Enterprise Value 35.44B 287M 248M 232M 213M 402M 27.27B 406M 2.72B 1.07B 13.64B 1.08B 1.05B 45.18B EV / Sales 2024
4.25x
EV / Sales 2025 2.74x
Free-Float
36.94%
Yield 2024
1.3%
Yield 2025 1.98%
1 week+0.37%
Current month+0.09%
1 month-5.48%
3 months+2.36%
6 months+3.92%
Current year+3.82%
1 week 108
Extreme 108
110.2
1 month 107
Extreme 107
117
Current year 96
Extreme 96
117.9
1 year 96
Extreme 96
147.5
3 years 92.4
Extreme 92.4
288.9
5 years 92.4
Extreme 92.4
393
10 years 16
Extreme 16
393
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 42 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.37%-4.06%-55.67% 203M
+4.86%-3.32%+52.73%+160.26% 1,043B
+1.04%-2.99%+50.87%+52.38% 621B
+0.98%-6.49%+24.00%+66.66% 435B
+0.45%+3.74%+47.47%+38.42% 361B
+0.82%-1.01%+35.87%+39.68% 293B
-0.12%-5.39%+8.87%+10.55% 251B
+4.57%+5.21%+35.91%+67.64% 220B
+1.24%-9.99%+2.88%-45.42% 201B
-2.58%-0.73%+17.16%+67.46% 164B
Average +0.35%-3.39%+27.17%+40.20% 358.93B
Weighted average by Cap. +0.72%-3.79%+38.50%+76.24%

Financials

2024 2025
Net sales 10.7B 86.58M 74.99M 69.9M 64.29M 121M 8.23B 123M 821M 322M 4.12B 325M 318M 13.64B 12.54B 101M 87.89M 81.93M 75.35M 142M 9.65B 144M 963M 378M 4.83B 381M 373M 15.99B
Net income 521M 4.22M 3.65M 3.4M 3.13M 5.91M 401M 5.98M 39.99M 15.7M 201M 15.83M 15.48M 664M 947M 7.66M 6.63M 6.18M 5.69M 10.74M 728M 10.86M 72.65M 28.52M 364M 28.76M 28.13M 1.21B
Net Debt 10B 80.88M 70.05M 65.3M 60.06M 113M 7.69B 115M 767M 301M 3.85B 304M 297M 12.74B 9.96B 80.61M 69.82M 65.08M 59.86M 113M 7.66B 114M 765M 300M 3.84B 303M 296M 12.7B
Logo Beacon Pharmaceuticals PLC
Beacon Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products, and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract and toll manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics, and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral, and biotech. Its products include Tagrix 80, Afanix 40, Ibrutix, Lenvanix 4, Palbonix, Crizonix, Sunitix, Wedica, Tafecta, Hernix, Obetix, Ribotix, among others.
Employees
4,771
Date Price Change Volume
04/08/26 BDT 108.60 0.00% 183,925
03/08/26 BDT 108.60 +0.09% 155,831
02/08/26 BDT 108.50 0.00% 106,204
30/07/26 BDT 108.50 +0.28% 197,132
29/07/26 BDT 108.20 -1.64% 394,745
  1. Stock Market
  2. Stocks
  3. BEACONPHAR Stock